For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Valo Early Discovery, Inc.

USPTO Granted Patents = 15

Forward Citations = 80

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

David R Lancia, Jr (12 out of 112 patents)

Pui Yee Ng (10 out of 78 patents)

Xiaozhang Zheng (8 out of 105 patents)

4. Mary-Margaret Zablocki (7 out of 48 patents)

5. Aleksandra Rudnitskaya (7 out of 52 patents)

6. Stephanos Ioannidis (7 out of 39 patents)

7. Jennifer R Thomason (6 out of 45 patents)

8. Bingsong Han (6 out of 74 patents)

9. Cuixian Liu (6 out of 54 patents)

10. Kenneth W Bair (6 out of 82 patents)

11. Matthew W Martin (5 out of 73 patents)

12. Bruce Follows (5 out of 29 patents)

13. Minghua Wang (5 out of 31 patents)

14. Ann-Marie Campbell (5 out of 59 patents)

15. Adam Charles Talbot (5 out of 32 patents)

15 patents: Sort by Forward Citations

1. 10988450 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2021-04-27),

2. 10988441 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2021-04-27),

3. 10981915 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2021-04-20),

4. 10934299 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2021-03-02),

5. 10927130 - Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-23),

6. 10913753 - Thienopyridine carboxamides as ubiquitin-specific protease inhibitors (2021-02-09),

7. 10906916 - Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-02),

8. 10889592 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2021-01-12),

9. 10874649 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors (2020-12-29),

10. 10870645 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors (2020-12-22),

11. 10836741 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2020-11-17),

12. 10829462 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2020-11-10),

13. 10829461 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2020-11-10),

14. 10829460 - [6,6] fused bicyclic HDAC8 inhibitors (2020-11-10),

15. 10822316 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2020-11-03),

Valo Early Discovery, Inc. is a biotechnology company specializing in the development and commercialization of innovative early-stage drug discovery technologies. With a talented team of scientists and cutting-edge research facilities, Valo Early Discovery is committed to accelerating the identification and validation of novel drug targets. Their goal is to revolutionize the drug discovery process and advance the development of new treatments for a wide range of diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

15 Patents

#144 in Boston, MA

#1,230 in Massachusetts

#20,400 in US

#38,669 in the World

Boston, MA, United States of America

Valo Early Discovery, Inc.

Forward Citations = 80

30 inventors:

David R Lancia, Jr (12 out of 112 patents)

Pui Yee Ng (10 out of 78 patents)

Xiaozhang Zheng (8 out of 105 patents)

4. Mary-Margaret Zablocki (7 out of 48 patents)

5. Aleksandra Rudnitskaya (7 out of 52 patents)

Please report any incorrect information to support@idiyas.com

Loading…